As plan sponsors continue to look for ways to control drug plan spending, a new study from the University of British Columbia shows that switching from an open to a closed formulary can save big dollars. The study, published this month in the Canadian Medical Association Journal Open, analyzed what happened when the B.C. Hospital […]
On Friday, the federal government announced the final amendments to the Patented Medicine Prices Review Board regulations, estimating the reforms will save Canadians about $13 billion in the next decade and lay the foundation for national pharmacare. The amendments, which were put forward by the government in a consultation in May 2017, include an update […]
Prince Edward Island has added six new drugs to the provincial formulary. People dealing with arthritis, diabetes, chronic obstructive pulmonary disease, lung cancer, heart failure and those receiving radiation therapy will now have help in paying for prescription medications. The promise to help provide better access to medications was made in the 2019-20 provincial budget […]
Plan sponsors are increasingly adopting plan design tools to manage their drug plan costs, according to Telus Health’s annual drug trends report. It found private plan drug costs have grown 0.3 per cent per year on average for the past 10 years, made up of an average 2.1 per cent annual decrease in the cost […]
If the Canada-United States-Mexico trade agreement goes through it could have a significant impact on the cost of private drug plans. Currently on hold until members of Parliament return to Ottawa after the summer break, the agreement as written would extend the data protection term for biologic drugs to 10 years from the current eight. If […]
Plan sponsors and plan members are unaware of the key differences between private and public drug plans, according to the 2019 Sanofi Canada health-care survey. Both employer and employee respondents said they believe private and public prescription drug plans cover close to the same amount of medications. Plan members estimated about 6,600 drugs are covered under private […]
If the Canadian government wants to tackle drug coverage, it should focus on the areas where Canadians are facing genuine gaps, according to Joe Farago, executive director of health-care innovation at Innovative Medicines Canada. “The reality is only 1.8 per cent of Canadians have no form of private or public drug coverage,” said Farago, speaking at Benefits […]
If the Canadian government wants to tackle drug coverage, it should focus on the areas where Canadians are facing genuine gaps, according to Joe Farago, executive director of health-care innovation at Innovative Medicines Canada. “The reality is only 1.8 per cent of Canadians have no form of private or public drug coverage,” said Farago, speaking at Benefits […]
British Columbia is expanding its use of biosimilars, effective November 2019. The move is expected to create opportunities for new drug listings and increase current coverage for patients, according to a press release from the B.C. government. The first two drugs to come into immediate effect are Jardiance, a diabetes drug, and Taltz, an arthritis drug. It will change the game considerably, says Suzanne Lepage, a private […]
Drug plan design changes are often unavoidable, whether they’re due to a carrier modifying contracts across the board or an employer looking to manage ballooning costs. Generally, “plan sponsors are looking at programs like more managed formularies and, potentially, maximums,” says Suzanne Lepage, a private health plan strategist in Kitchener, Ont. “Changes driven at the […]